Dog Mast Cell Tumour: Diagnosis, Staging, and Quality of Life Management

Mast cell tumours are the most common malignant skin tumour in dogs. Accurate staging and tailored treatment plans can achieve long-term remission with maintained quality of life.

Key Facts

Mast cell tumours represent around 20% of all canine skin tumours
Breeds at higher risk include Boxers, Pugs, Labrador Retrievers, and Golden Retrievers
WHO grading (Grade 1-3 or Patnaik system) guides treatment intensity
Surgical excision with adequate margins is curative for low-grade tumours
Tyrosine kinase inhibitors (toceranib/masitinib) are effective targeted therapies for inoperable or high-grade tumours
Pruritus and local oedema from histamine release cause significant welfare problems in uncontrolled disease

Welfare Considerations

Mast cell tumours vary enormously in behaviour - some are cured by simple surgical removal while others are aggressive and life-threatening. The welfare priority is accurate diagnosis and staging to match treatment intensity to disease severity. Dogs with controlled disease may have excellent quality of life for years, while those with inadequately treated tumours experience progressive discomfort from histamine-mediated inflammation. Regular monitoring after treatment detects recurrence before it compromises welfare.

What You Can Do

Have any new skin lump on your dog fine-needle aspirated before surgical removal
Request histopathology with grading on all excised tumours
Discuss staging investigations (lymph node aspirate, abdominal ultrasound) with your vet
Ask about tyrosine kinase inhibitors if your dog has an inoperable or recurrent high-grade tumour
Monitor treated dogs every 3 months for recurrence